A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

ALX-0061

BIOLOGICAL

Placebo

BIOLOGICAL

Tocilizumab

Trial Locations (83)

1000

Investigator Site 1, Skopje

Investigator Site 2, Skopje

1200

Investigator Site, Brussels

2025

Investigator Site, Chisinau

3800

Investigator Site, Szikszó

4000

Investigator Site, Liège

5700

Investigator site, Gyula

6500

Investigator Site, Baja

8000

Investigator Site, Székesfehérvar

8200

Investigator Site, Veszprém

9000

Investigator Site, Ghent

9700

Investigator Site, Szombathely

10018

Investigator Site, New York

20582

Investigator Site, Lublin

28007

Investigator Site, Madrid

29406

Investigator Site, Charleston

30281

Investigator Site, Stockbridge

32804

Investigator Site, Orlando

33016

Investigator site, Hialeah

33030

Investigator Site, Homestead

35216

Investigator Site, Birmingham

38119

Investigator Site, Memphis

39300

Investigator Site, Santander

60773

Investigator SIte, Poznan

66209

Investigator site, Overland Park

70300

Investigator Site, Ostrava

75150

Investigator Site, Mesquite

82300

Investigator Site 2, Elblag

87100

Investigator Site, Torun

87102

Investigator Site, Albuquerque

90017

Investigator site, Los Angeles

90036

Investigator Site, Los Angeles

90712

Investigator Site, La Palma

92543

Investigator Site, Hemet

93003

Investigator site, Ventura

96500

Investigator Site, Sochaczew

602000

Investigator Site, Brno

01605

Investigator Site, Worcester

Unknown

Investigator Site, Burgas

Investigator Site, Pleven

Investigator Site 1, Plovdiv

Investigator Site 2, Plovdiv

Investigator Site 1, Rousse

Investigator Site 2, Rousse

Investigator Site, Sofia

Investigator Site, Olomouc

Investigator Site 1, Prague

Investigator Site 2, Prague

Investigator Site, Zlín

Investigator Site, Berlin

Investigator Site, Frankfurt

Investigator Site, Hamburg

Investigator Site, Budapest

Investigator Site, Esztergom

Investigator Site, Culiacán

Investigator Site, León

Investigator Site 1, Mexico City

Investigator Site 2, Mexico City

Investigator Site, Mexico City

Investigator Site 1, Monterrey

Investigator Site 2, Monterrey

Investigator Site, Chisinau

Investigator Site, Bydgoszcz

Investigator Site, Elblag

Investigator Site, Gdynia

Investigator Site, Bucharest

Investigator Site, Oradea

Investigator Site, Timișoara

Investigator Site 1, Belgrade

Investigator Site 2, Belgrade

Investigator Site 3, Belgrade

Investigator Site, Niška Banja

Investigator Site, Córdoba

Investigator Site 2, Santander

Investigator Site 1, Santiago de Compostela

Investigator Site 2, Santiago de Compostela

0102

Investigator Site, Tbilisi

0159

Investigator Site 1, Tbilisi

Investigator Site 2, Tbilisi

0160

Investigator Site, Tbilisi

0179

Investigator Site, Tbilisi

05825

Investigator Site, Grodzisk Mazowiecki

02653

Investigator Site, Warsaw

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT02287922 - A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter